

DAFTAR PUSTAKA

1. Sukandar, E.Y., Andrajati, R., Sigit. J.I, Adnyana, I.K., Setiadi AAPS. K. ISO Farmakoterapi, Jilid 1. Jakarta, Indonesia: PT ISFI; 2013.
2. Kementerian Kesehatan RI. Formularium Ilmu Penyakit Dalam (Direktorat & J. B. K. dan A. Kesehatan (eds.). Indonesia: Kementerian Kesehatan RI; 2012.
3. Dipiro J.T., Yee G.C., Posey L.M., Haines S.T., Nolin T.D and Ellingrod V. Pharmacotherapy A Pathophysiologic Approach eleventh edition. Hill, New York; 2020.
4. R WO, Zuleta MG, P LO. Update on Approaches to Patients with Dyspepsia and Functional Dyspepsia. 2014;129–34.
5. Duckworth M, Ra P, Isa È, Nen È, Talley NJ, Pare P. Ef ® cacy of omeprazole in functional dyspepsia : double-blind , randomized , placebo-controlled trials (the Bond and Opera studies). 1998;
6. Sari MN. Evaluasi Rasionalitas Penggunaan Kombinasi Obat Pada Pasien Tukak Lambung di Ruang Rawat Inap RSUD dr. Soebandi Jember. Universitas Jember; 2012.
7. RB P. Potensi interaksi Obat Pada Pasien Gangguan Lambung (Dispepsia, Gastritis, Tukak Peptik) Rawat Inap di Rumah Sakit “X” Tahun 2015. Universitas Muhammadiyah Surakarta; 2016.
8. Putri AA. Identifikasi Interaksi Obat Tukak Lambung Pada Pasien geriatic di RSUP Dr. M. Djamil Padang. Universitas Andalas; 2018.
9. Snyder BD, Polasek TM, Doogue MP. Drug interactions: Principles and practice. Aust Prescr. 2012;35(3):85–8.
10. Stockley. Stockley’s Drug Interaction, 8th Edition. London: Pharmaceutical Press; 2008.
11. Cascorbi I. Drug Interactions — Principles , Examples and Clinical Consequences. 2012;109:546–57.
12. Setiawati A. Interaksi Obat dalam Gunawan, S.G 2007, Farmakologi dan Terapi, Edisi 5. Jakarta: Bagian Farmakologi dan Terapeutik Fakultas

Kedokteran UI; 2007.

13. Rikomah S. Farmasi Klinik Rikomah S. Yogyakarta: Deepublish; 2018.
14. Tatro DS. Drug Interaction Facts. United State of America: Wolte rKluwer Health; 2008.
15. Scott A, Scott GN, Pharm BS. Mechanisms of Drug Interactions. 2013;18(3):1–20.
16. Aslam M, Kaw Tan C PA. Farmasi Klinis (Clinical Pharmacy) Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien. Jakarta: Elex Media Komputindo; 2003.
17. Şahne BS. An overview of polypharmacy in geriatric patients, in: challenges in elder care. 2016;69–80.
18. Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and Risk of Polypharmacy among the Elderly in an Outpatient Setting A Retrospective Cohort Study in the Emilia-Romagna Region , Italy. 2010;27(12):1019–28.
19. Fauziah H, Mulyana R MR. Polifarmasi pada pasien geriatri. Care, J Hum. 2020;5(3):804–12.
20. Hunfeld NG. Clinical Effects of Proton Pump Inhibitor- Focus on Pharmacogenetics, Kinetics and Dynamics. 2010;11–7.
21. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug Saf. 2014;37(4):201–11.
22. Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol [Internet]. 2021;56(4):303–22. Available from: <https://doi.org/10.1007/s00535-021-01769-0>
23. Sanusi, I.A A. Rani, M. S. K. & AFS (Eds. . Tukak Lambung. Buku Ajar Gastroenterologi. Jakarta: Interna Publishing; 2011. 328–345 p.
24. Sherwood L. Fisiologi Manusia: dari Sel ke Sistem Edisi 8, EGC. Jakarta; 2014.
25. Lockrey G, Lim L. Peptic ulcer disease in older people. J Pharm Pract Res. 2011;41(1):58–61.

26. Gosal.F. Paringkoan.B., Wenas.N.T. Patofisiologi dan Penanganan Gastropati Obat Antiinflamasi Nonsteroid. *J Indones Med.* 2012;62:446.
27. Saputri FC, Munim A. Pengembangan Metode Induksi Tukak Lambung. *Pharm Sci Res.* 2008;5(2).
28. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: A global perspective. *World J Gastroenterol.* 2006;12(17):2661–6.
29. Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: Overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. *Gut.* 2003;52(4):600–8.
30. Boekema PJ, Samsom M, Van Berge Henegouwen GP, Smout AJPM. Coffee and gastrointestinal function: Facts and fiction: A review. *Scand J Gastroenterol Suppl.* 1999;33(34):35–9.
31. Djojoningrat D. Dispepsia Fungsional. In S. B. Setiati S, Alwi I, Sudoyo AW, Simadibrata M (Ed.), *Buku ajar ilmu penyakit dalam* (6th ed.). Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia.; 2014.
32. Kim SE, Park YS, Kim N, Kim MS, Jo HJ, Shin CM, et al. Effect of *Helicobacter pylori* eradication on functional Dyspepsia. *J Neurogastroenterol Motil.* 2013;19(2):233–43.
33. Susanti A, Briawan D, Urip V. Faktor Risiko Dispepsia pada Mahasiswa Institut Pertanian Bogor (IPB). *J Kedokt Indones.* 2011;2(1):80–91.
34. National institute for clinical Excellence (NICE). Quick Reference Guide Dyspepsia Management Dyspepsia in adults in Primary Care. Clinical G. London: NICE; 2004.
35. Fugit, R. V., & Berardi R. No TitleUpper Gastrointestinal Disorder. In M. A. Koda-Kimble, L. Y. Young, B. KAlldredge, R. L. Corelli, B. J. Guglielmo, W. A. Kradjan, & Bradley R Williams (Eds.), *Applied Therapeutics the Cinical Use of Drugs* (9th ed.) [Internet]. *Annals of Internal Medicine*; 2009. Available from: https://doi.org/10.7326/0003-4819-99-4-582_4
36. Kindiasari D. Pola Penggunaan Proton Pump Inhibitor (PPI) Pada Pasien

Dispepsia. Universitas Airlangga Surabaya; 2017.

37. Flood, P., Rathmell, J., & Shafer S. Stoelting's Pharmacology and Physiology in Anesthetic Practice (Fifth Edit). Library of Congress Cataloging; 2015.
38. Monkemuller, K., Malfertheiner, P. Drug treatment of functional dyspepsia. 2006;12(17):2694–700.
39. Allescher HD, Böckenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: A meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol. 2001;36(9):934–41.
40. Dobrilla, G., Comberlato, M., Steele, A., & Vallaperta P. Drug treatment of functional dyspepsia: A meta-analysis of randomized controlled clinical trials. Journal of Clinical Gastroenterology,. 1989;11(2):169–77. Available from: <https://doi.org/10.1097/00004836-198904000-00011%0D>
41. Moayyedi, P., Soo, S., Deeks, J. J., Delaney, B., Harris, A., Innes, M., Oakes R, Wilson, S., Roalfe, A., Bennett, C., & Forman D. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews; 2006.
42. Kluwr W. Drug Interaction Checker. American Society of Health System Pharmacists CM and, Health M form T.
43. RI D. Undang-Undang Nomor 36 Tahun 2009 tentang Kesehatan [Internet]. 2009. Available from: [http://www.depkes.go.id/resources/download/general/UU Nomor 36 Tahun 2009 tentang Kesehatan.pdf](http://www.depkes.go.id/resources/download/general/UU%20Nomor%2036%20Tahun%20tentang%20Kesehatan.pdf)
44. Widayat W, Ghassani IK, Rijai L. Profil Pengobatan dan DRP'S pada Pasien Gangguan Lambung (Dyspepsia, Gastritis, Peptic Ulcer) Di RSUD Samarinda. J Sains dan Kesehat. 2018;1(10):539–47.
45. Herdaningsih S, Muhtadi A, Lestari K, Annisa N. Potential of Drug-Drug Interaction in Polypharmacy Prescription: Retrospective Study on a Drugstore in Bandung. Indones J Clin Pharm. 2016;5(4):288–92.
46. Rizqah, Nur'aini FN. EVALUASI PENGGUNAAN OBAT TUKAK PEPTIK PADA PASIEN TUKAK PEPTIK (Peptic Ulcer Disease) DI RUMAH SAKIT

BHAYANGKARA BRIMOB TAHUN 2015. 2016;III(2).

47. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509–33.
48. Robinson M. The pharmacodynamics and pharmacokinetics of proton pump inhibitors - Overview and clinical implications. Aliment Pharmacol Ther Suppl. 2004;20(6):1–10.
49. Arfania M. Analisis Hubungan Faktor Risiko Dengan Kejadian Interaksi Obat Potensial Pasien Geriatri Di Rumah Sakit Swasta Yogyakarta. Pharma Xplore J Ilm Farm. 2017;2(1):2006–8.
50. Mohamed Aslam. Interaksi obat dalam Farmasi Klinis (Clinic Pharmacy) Menuju Pengobatan Rasional dan Penghargaan pilihan pasien. PT Alex Me. Jakarta; 2003. 119–134 p.
51. Rahmawati F, Handayani R G V. A Retrospective Study On Drug Interaction in Dr. Sardjito Hospital Yogyakarta. Farm Indones. 2006;17.
52. Fadilah H, Indria DM, Wibiso N. Hubungan Polifarmasi dengan Potensi Interaksi Obat pada Pasien yang Mendapatkan Resep Obat Antihiperlipidemia. J Bio Komplementer Med. 2023;10(1):1–13.

